E
E. W. Radü
Researcher at University Hospital of Basel
Publications - 17
Citations - 1940
E. W. Radü is an academic researcher from University Hospital of Basel. The author has contributed to research in topics: Expanded Disability Status Scale & At risk mental state. The author has an hindex of 11, co-authored 17 publications receiving 1825 citations. Previous affiliations of E. W. Radü include University of Basel.
Papers
More filters
Journal ArticleDOI
Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study
Ludwig Kappos,Mark S. Freedman,Chris H. Polman,Gilles Edan,Hans-Peter Hartung,David Miller,Xavier Montalban,Frederik Barkhof,E. W. Radü,Lars Bauer,S Dahms,Vivian Lanius,Christoph Pohl,Christoph Pohl,Rupert Sandbrink +14 more
TL;DR: The data suggest that early initiation of treatment with interferon beta-1b prevents the development of confirmed disability, supporting its use after the first manifestation of relapsing-remitting MS.
Journal ArticleDOI
Vitamin D as an early predictor of multiple sclerosis activity and progression.
Alberto Ascherio,Kassandra L. Munger,Rick White,Karl Köchert,Kelly Claire Simon,Chris H. Polman,Mark S. Freedman,Hans-Peter Hartung,David Miller,Xavier Montalban,Gilles Edan,Frederik Barkhof,Dirk Pleimes,E. W. Radü,Rupert Sandbrink,Ludwig Kappos,Christoph Pohl +16 more
TL;DR: Among patients with MS mainly treated with interferon beta-1b, low 25(OH)D levels early in the disease course are a strong risk factor for long-term MS activity and progression.
Journal ArticleDOI
Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial
Ludwig Kappos,Mark S. Freedman,Chris H. Polman,Gilles Edan,Hans Peter Hartung,David Miller,Xavier Montalban,Frederik Barkhof,E. W. Radü,Carola Metzig,Lars Bauer,Vivian Lanius,Rupert Sandbrink,Rupert Sandbrink,Christoph Pohl,Christoph Pohl +15 more
TL;DR: Effects on the rate of conversion to CDMS and the favourable long-term safety and tolerability profile support early initiation of treatment with interferon beta-1b, although a delay in treatment by up to 2 years did not affect long- term disability outcomes.
Journal ArticleDOI
Regional gray matter volume abnormalities in the at risk mental state
Stefan Borgwardt,Anita Riecher-Rössler,Paola Dazzan,Xavier Chitnis,Jacqueline Aston,M. Drewe,Ute Gschwandtner,Sven Haller,Marlon Pflüger,E. Rechsteiner,Marcus D’Souza,Rolf-Dieter Stieglitz,E. W. Radü,Philip McGuire +13 more
TL;DR: The ARMS was associated with reductions in gray matter volume in areas that are also reduced in schizophrenia, suggesting that these are a correlate of an increased vulnerability to psychosis.
Journal ArticleDOI
Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy
Olaf Stüve,Olaf Stüve,Olaf Stüve,PD Cravens,Elliot M. Frohman,JT Phillips,Gina Remington,G. von Geldern,Sabine Cepok,Mahendra Singh,J. W. Cohen Tervaert,M. De Baets,D. G. MacManus,DH Miller,E. W. Radü,Elizabeth M. Cameron,Nancy L. Monson,Song Zhang,R Kim,B. Hemmer,Michael K. Racke +20 more
TL;DR: This is the first long-term follow-up of patients who discontinued natalizumab and did not observe a clinical, radiographic, or immunologic rebound phenomenon after discontinuation of natalIZumab therapy.